Citation

Fétique-Will AC, Chevalley T, Rizzoli R. Rev. Med. Suisse 2011; 7(299): 1299-1304.

Vernacular Title

Inhibiteurs selectifs de la recapture de la serotonine (ISRS) et osteoporose.

Affiliation

Service de psychiatrie générale, Département de santé mentale et de psychiatrie, HUG, 121I Genève 14. anne-catherine.will-fetique@hcuge.ch

Copyright

(Copyright © 2011, Medecine et Hygiene)

DOI

unavailable

PMID

21793419

Abstract

Selective serotonin reuptake inhibitors (SSRI) represent the first-line treatment of depression. Several studies demonstrate that use of therapeutical doses of SSRI is associated with a decreased bone mineral density (BMD) and an increased risk of fracture. Mechanisms of action of SSRI on bone tissue are not totally clarified. These treatments would be associated with an increased risk of falls and would also have a direct effect on bone metabolism. Regarding proofs existing of the implication of SSRI on osteoporosis, while waiting for larger-scale prospective studies, it appears reasonable that practitioners assess bone loss within risk groups of patients treated with SSRI.

Language: fr